1609452-30-3Cc1c(Br)c(Br)c2c3c1nc(N1CCNCC1)n3CCC2FSBMCTDYWXIBLM-UHFFFAOYSA-NRomaciclib is an orally bioavailable inhibitor of cyclin-dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and chemoprotective activities. Upon oral administration, romaciclib targets, binds to and inhibits the activity of CDK8/19, which prevents activation of CDK8/19-mediated oncogenic signaling pathways, blocks selective transcription of various tumor-promoting genes, and inhibits proliferation of CDK8/19-overexpressing tumor cells. CDK8/19, serine/threonine kinases involved in the regulation of the cell cycle, are overexpressed in certain cancer cell types and play key roles in tumor cell proliferation.
使用CDK8-IN-2, a CDK8 and/or CDK19 inhibitor.
読み込み中…
読み込み中…
現在のフィルター条件では反応記録がありません。
読み込み中…
1609452-30-3、1609522-33-9CHEMBL4225966